Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534723 | 1.00 | TRPA1 (0.56) | TRPA1CYP2D6MAOBNPC1RAB9A | |
| SCHEMBL933101 | 0.81 | TRPA1 (0.56) | TRPA1CYP2D6MAOBTAAR1SLC6A2 | |
| SCHEMBL21852752 | 0.79 | TRPA1 (0.69) | TRPA1CYP2D6NPC1RAB9ATAAR1 | |
| SCHEMBL234669 | 0.79 | TRPA1 (0.69) | TRPA1CYP2D6NPC1RAB9ATAAR1 | |
| SCHEMBL19725385 | 0.79 | TRPA1 (0.69) | TRPA1CYP2D6NPC1RAB9ATAAR1 | |
| Water SCHEMBL3896311 | 0.79 | TRPA1 (0.74) | TRPA1CYP2D6MAOBTAAR1SLC6A2 | |
| SCHEMBL4951816 | 0.77 | TRPA1 (0.67) | TRPA1CYP2D6NPC1RAB9ATAAR1 | |
| SCHEMBL11412673 | 0.77 | EPHX1 (0.48) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL8690443 | 0.77 | EPHX1 (0.48) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL27313237 | 0.77 | CYP2D6 (0.62) | TRPA1CYP2D6MAOBTAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | TRPA1 3380/4885CYP2D6 3181/4885MAOB 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.